LipoScience (LPDX)
has developed a blood test (NMR LipoProfile) that has the potential to
meaningfully improve outcomes for patients at risk of
cholesterol-related cardiovascular problems, but it takes more than an
FDA-approved test to make a business work. LipoScience is perilously
close to becoming a company with a great future in its past, as the
company continues to struggle to generate commercial interest in its
test. A journal article based upon a retrospective analysis of LDL-P
measurement could help spur interest and a takeover is a credible
potential outcome, but LipoScience's current circumstances make this a
highly speculative stock.
Please read more here:
LipoScience Nearly Back To Square One
No comments:
Post a Comment